Practical Considerations for Antibodies in Myeloma

Jacob P. Laubach, Niels van de Donk, Faith E. Davies, Joseph R Mikhael

Research output: Contribution to journalReview article

Abstract

The development of the monoclonal antibodies daratumumab and elotuzumab has expanded treatment options for multiple myeloma and led to great improvement in patient outcomes. These agents have favorable safety profiles and synergize effectively with established agents used in the management of myeloma, namely immunomodulatory drugs and proteasome inhibitors. This article reviews the rationale for use of monoclonal antibodies in myeloma, current approved indications for daratumumab and elotuzumab, the manner in which these agents are used in the overall management of myeloma, and specific challenges associated with their use in the clinic. It also highlights other, emerging drug combinations that incorporate daratumumab or elotuzumab and profiles new therapeutic antibodies currently under development.

Original languageEnglish (US)
Pages (from-to)667-674
Number of pages8
JournalAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Issue number38
DOIs
StatePublished - May 23 2018
Externally publishedYes

Fingerprint

Antibodies
Monoclonal Antibodies
Proteasome Inhibitors
Drug Combinations
Multiple Myeloma
Safety
Therapeutics
Pharmaceutical Preparations
daratumumab
elotuzumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Practical Considerations for Antibodies in Myeloma. / Laubach, Jacob P.; van de Donk, Niels; Davies, Faith E.; Mikhael, Joseph R.

In: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, No. 38, 23.05.2018, p. 667-674.

Research output: Contribution to journalReview article

Laubach, Jacob P. ; van de Donk, Niels ; Davies, Faith E. ; Mikhael, Joseph R. / Practical Considerations for Antibodies in Myeloma. In: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2018 ; No. 38. pp. 667-674.
@article{094a1ef075fb470c83ba52245e05713f,
title = "Practical Considerations for Antibodies in Myeloma",
abstract = "The development of the monoclonal antibodies daratumumab and elotuzumab has expanded treatment options for multiple myeloma and led to great improvement in patient outcomes. These agents have favorable safety profiles and synergize effectively with established agents used in the management of myeloma, namely immunomodulatory drugs and proteasome inhibitors. This article reviews the rationale for use of monoclonal antibodies in myeloma, current approved indications for daratumumab and elotuzumab, the manner in which these agents are used in the overall management of myeloma, and specific challenges associated with their use in the clinic. It also highlights other, emerging drug combinations that incorporate daratumumab or elotuzumab and profiles new therapeutic antibodies currently under development.",
author = "Laubach, {Jacob P.} and {van de Donk}, Niels and Davies, {Faith E.} and Mikhael, {Joseph R}",
year = "2018",
month = "5",
day = "23",
doi = "10.1200/EDBK_205443",
language = "English (US)",
pages = "667--674",
journal = "American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting",
issn = "1548-8756",
publisher = "American Society of Clinical Oncology",
number = "38",

}

TY - JOUR

T1 - Practical Considerations for Antibodies in Myeloma

AU - Laubach, Jacob P.

AU - van de Donk, Niels

AU - Davies, Faith E.

AU - Mikhael, Joseph R

PY - 2018/5/23

Y1 - 2018/5/23

N2 - The development of the monoclonal antibodies daratumumab and elotuzumab has expanded treatment options for multiple myeloma and led to great improvement in patient outcomes. These agents have favorable safety profiles and synergize effectively with established agents used in the management of myeloma, namely immunomodulatory drugs and proteasome inhibitors. This article reviews the rationale for use of monoclonal antibodies in myeloma, current approved indications for daratumumab and elotuzumab, the manner in which these agents are used in the overall management of myeloma, and specific challenges associated with their use in the clinic. It also highlights other, emerging drug combinations that incorporate daratumumab or elotuzumab and profiles new therapeutic antibodies currently under development.

AB - The development of the monoclonal antibodies daratumumab and elotuzumab has expanded treatment options for multiple myeloma and led to great improvement in patient outcomes. These agents have favorable safety profiles and synergize effectively with established agents used in the management of myeloma, namely immunomodulatory drugs and proteasome inhibitors. This article reviews the rationale for use of monoclonal antibodies in myeloma, current approved indications for daratumumab and elotuzumab, the manner in which these agents are used in the overall management of myeloma, and specific challenges associated with their use in the clinic. It also highlights other, emerging drug combinations that incorporate daratumumab or elotuzumab and profiles new therapeutic antibodies currently under development.

UR - http://www.scopus.com/inward/record.url?scp=85056029998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056029998&partnerID=8YFLogxK

U2 - 10.1200/EDBK_205443

DO - 10.1200/EDBK_205443

M3 - Review article

SP - 667

EP - 674

JO - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

JF - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

SN - 1548-8756

IS - 38

ER -